Interactions between PPAR-α and inflammation-related cytokine genes on the development of Alzheimer's disease, observed by the Epistasis project

International Journal of Molecular Epidemiology and Genetics

Volumn 3, Issue 1, 2012, Pages 39-47

  Heun, Reinhard ^a,b   Kölsch, Heike ^a   Ibrahim Verbaas, Carla A ^c   Combarros, Onofre ^d   Aulchenko, Yurii S ^c   Breteler, Monique ^c   Schuur, Maaike ^c   van Duijn, Cornelia M ^c   Hammond, Naomi ^e   Belbin, Olivia ^f   Cortina Borja, Mario ^g   Wilcock, Gordon K ^h   Brown, Kristelle ⁱ   Barber, Rachel ⁱ   Kehoe, Patrick G ^j   Coto, Eliecer ^j   Alvarez, Victoria ^k   Lehmann, Michael G ^e   Deloukas, Panos ^d   Mateo, Ignacio ^f   Morgan, Kevin ^k   Warden, Donald R ^k   Smith, A David ^k   Lehmann, Donald J ^k   more..

^a UNIVERSITY OF BONN   (Germany)

^b ROYAL DERBY HOSPITAL   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CANTABRIA   (Spain)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ UNIVERSITY OF BRISTOL   (United Kingdom)

^j HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^k UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

AD; Epistasis; Genetic interaction; Genetics; Inflammation; Interleukin; PPAR alpha; Sporadic; Steroid receptors

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; INFLAMMATION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84863372774     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Johnston H, Boutin H, Allan SM. Assessing the contribution of inflammation in models of Alzheimer's disease. iochem oc Trans. 2011;39:886-90.
2. Griffin WS, Stanley LC, Ling C, White L, Ma-cLeod V, Perrot LJ, White CL 3rd, Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86:7611-5.
3. Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry. 2010;68:930-41.
4. Shaftel SS, Griffin WS, O'Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation. 2008;5:7.
5. Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin WS. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging. 1996;17:761-6.
6. Quintanilla RA, Orellana DI, González-Billault C, Maccioni RB. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res. 2004;295:245-57.
7. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, Reddy JK (1995) Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPARgamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci USA 92:7921-7925.
8. Escher P, Wahli W. Peroxisome proliferator-acti-vated receptors: insight into multiple cellular functions. Mutat Res. 2000;448:121-38.
9. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405:421-4.
10. De la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunc-Int J Mol Epidemiol tion occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis. 2006;9:167-81.
11. Combs CK, Bates P, Karlo JC, Landreth GE. Regulation of beta-amyloid stimulated proin-flammatory responses by peroxisome prolifera-tor-activated receptor alpha. Neurochem Int. 2001;39:449-57.
12. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schürmann B, Heun R, Kölsch H, van den Bussche H, Heuser I, Peters O, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Rüther E, Carrasquillo MM, Pankratz VS, Younkin SG, Hardy J, O'Donovan MC, Owen MJ, Williams J. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One. 2010;5:e13950.
13. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Rüther E, Schürmann B, Heun R, Kölsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Gallacher J, Hüll M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC; Alzheimer's Disease Neuroimaging Initiative, van Duijn CM, Breteler MM, Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S; CHARGE consortium, Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alpe ́rovitch A, Lathrop M; EADI1 consortium, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Björnsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossù P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429-35.
14. Brune S, Kölsch H, Ptok U, Majores M, Schulz A, Schlosser R, Rao ML, Maier W, Heun R. Polymorphism in the peroxisome proliferator-activated receptor alpha gene influences the risk for Alzheimer's disease. J Neural Transm. 2003;110:1041-50.
15. Du Y, Dodel RC, Eastwood BJ, Bales KR, Gao F, Lohmüller F, Müller U, Kurz A, Zimmer R, Evans RM, Hake A, Gasser T, Oertel WH, Griffin WS, Paul SM, Farlow MR. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology. 2000;55:480-3.
16. Grimaldi LM, Casadei VM, Ferri C, Veglia F, Licastro F, Annoni G, Biunno I, De Bellis G, Sorbi S, Mariani C, Canal N, Griffin WS, Franceschi M. Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol. 2000;47:361-5.
17. Kölsch H, Ptok U, Bagli M, Papassotiropoulos A, Schmitz S, Barkow K, Kockler M, Rao ML, Maier W, Heun R. Gene polymorphisms of interleukin-1alpha influence the course of Alzheimer's disease. Ann Neurol. 2001;49:818-9.
18. Albani D, Tettamanti M, Batelli S, Polito L, Dusi S, Ateri E, Forloni G, Lucca U. Interleukin-1α, interleukin-1β and tumor necrosis factor-α genetic variants and risk of dementia in the very old: evidence from the "Monzino 80-plus" prospective study. Age (Dordr). 2011 Apr 21, Epub ahead of print.
19. Hu JL, Li G, Zhou DX, Zou YX, Zhu ZS, Xu RX, Jiang XD, Zeng YJ. enetic analysis of interleu-kin-1A C(-889)T polymorphism with Alzheimer disease. Cell Mol Neurobiol. 2009;29:81-5.
20. Vendramini AA, de Lábio RW, Rasmussen LT,Dos Reis NM, Minett T, Bertolucci PH, de Sou-za Pinhel MA, Souza DR, Mazzotti DR, de Arruda Cardoso Smith M, Payão SL. Interleukin-8-251T > A, Interleukin-1α-889C>T and Apolipoprotein E polymorphisms in Alzheimer's disease. Genet Mol Biol. 2011;34:1-5.
21. Déniz-Naranjo MC, Muñoz-Fernandez C, Ale-many-Rodríguez MJ, Pérez-Vieitez MC, Aladro-Benito Y, Irurita-Latasa J, Sánchez-García F. Cytokine IL-1 beta but not IL-1 alpha promoter polymorphism is associated with Alzheimer disease in a population from the Canary Islands, Spain. Eur J Neurol. 2008;15:1080-4.
22. Ehl C, Kölsch H, Ptok U, Jessen F, Schmitz S, Frahnert C, Schlösser R, Rao ML, Maier W, Heun R. Association of an interleukin-1beta gene polymorphism at position -511 with Alzheimer's disease. Int J Mol Med. 2003;11:235-8.
23. Bagli M, Papassotiropoulos A, Hampel H, Beck-er K, Jessen F, Bürger K, Ptok U, Rao ML, Möller HJ, Maier W, Heun R. Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study. Eur Arch Psychiatry Clin Neurosci. 2003;253:44-8.
24. Bagli M, Papassotiropoulos A, Knapp M, Jes-sen F, Luise Rao M, Maier W, Heun R. Associa-tion between an interleukin-6 promoter and 3' flanking region haplotype and reduced Alzheimer's disease risk in a German population. Neurosci Lett. 2000;283:109-12.
25. Papassotiropoulos A, Bagli M, Jessen F, Bayer TA, Maier W, Rao ML, Heun R. A genetic varia-tion of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease.Ann Neurol. 1999;45:666-8.
26. Zhang Y, Zhang J, Tian C, Xiao Y, Li X, He C,Huang J, Fan H. The -1082G/A polymorphism in IL-10 gene is associated with risk of Alzheimer's disease: a meta-analysis. J Neurol Sci. 2011;303:133-8.
27. Mirra SS, Heyman A, McKeel D, Sumi SM,Crain BJ, Brownlee LM, Vogel FS, Hughes JP,van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984; 34:939-944.
29. Combarros O, van Duijn CM, Hammond N, Bel-bin O, Arias-Vásquez A, Cortina-Borja M, Lehm-ann MG, Aulchenko YS, Schuur M, Kölsch H, Heun R, Wilcock GK, Brown K, Kehoe PG, Harrison R, Coto E, Alvarez V, Deloukas P, Mateo I, Gwilliam R, Morgan K, Warden DR, Smith AD, Lehmann DJ. Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease. J Neuroinflammation. 2009;6:22.
30. Combarros O, Warden DR, Hammond N, Cortina-Borja M, Belbin O, Lehmann MG, Wilcock GK, Brown K, Kehoe PG, Barber R, Coto E, Alvarez V, Deloukas P, Gwilliam R, Heun R, Kölsch H, Mateo I, Oulhaj A, Arias-Vásquez A, Schuur M, Aulchenko YS, Ikram MA, Breteler MM, van Duijn CM, Morgan K, Smith AD, Lehmann DJ. The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project. BMC Med Genet. 2010;11:162.
31. Kölsch H, Donald J Lehmann, Ibrahim-Verbaas CA, Combarros O, Van Duijn CM, Hammond N, Cortina-Borja M, Lehmann, MG, Aulchenko YS, Schuur M, Breteler M, Wilcock GK, Brown K, Kehoe PG, Barber R, Coto E, Alvarez V, Deloukas P, Mateo I, Maier W, Morgan K, Warden DR, Smith DA, Heun R, Interaction of insulin and PPAR-α genes in Alzheimer's disease: the Epistasis Project. J Neural Transm 2011 [Epub ahead of print]
32. Cortina-Borja M, Smith AD, Combarros O, Lehmann DJ. The synergy factor: a statistic to measure interactions in complex diseases. BMC Res Notes. 2009;2:105.
33. McGeer PL, McGeer EG. The inflammatory re-sponse system of brain: implications for thera-py of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. 1995;21:195-218.
34. Combs CK, Johnson DE, Karlo JC, Cannady SB,Landreth GE Inflammatory mechanisms in Al-zheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci. 2000;20:558-67.